Farruggia Piero, Macaluso Alessandra, Tropia Serena, Genova Selene, Paolicchi Olivia, Di Marco Floriana, D'Angelo Paolo
Pediatric Hematology and Oncology Unit, G. Di Cristina Children's Hospital, Palermo;
Pediatr Rep. 2011 Jun 16;3(2):e15. doi: 10.4081/pr.2011.e15.
Evans Syndrome is a rare autoimmune disease consisting of hemolytic anemia, thrombocytopenia and/or neutropenia. It may be associated with other autoimmune or lymphoproliferative diseases. Its course can be extremely serious and, rarely, even life-threatening; thus it represents a excellent treatment challenge for the pediatric hematologist. First line treatment consists of steroids and/or immunoglobulin; further therapy with rituximab, vincristine, cyclophosphamide and other immunosuppressive drugs can be considered in unresponsive patients. We describe a baby with refractory Evans Syndrome that was cured by prolonged administration of mycophenolate mofetil and remained disease-free for 4 years after the discontinuation of treatment.
伊文氏综合征是一种罕见的自身免疫性疾病,包括溶血性贫血、血小板减少和/或中性粒细胞减少。它可能与其他自身免疫性或淋巴增殖性疾病有关。其病程可能极其严重,极少数情况下甚至会危及生命;因此,对于儿科血液科医生来说,它是一个极具挑战性的治疗难题。一线治疗包括使用类固醇和/或免疫球蛋白;对于无反应的患者,可以考虑使用利妥昔单抗、长春新碱、环磷酰胺和其他免疫抑制药物进行进一步治疗。我们描述了一名患有难治性伊文氏综合征的婴儿,通过长期服用霉酚酸酯治愈,停药后4年无疾病复发。